293 related articles for article (PubMed ID: 10549711)
1. Production and chemical processing of low molecular weight heparins.
Linhardt RJ; Gunay NS
Semin Thromb Hemost; 1999; 25 Suppl 3():5-16. PubMed ID: 10549711
[TBL] [Abstract][Full Text] [Related]
2. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
3. Variability of heparins and heterogeneity of low molecular weight heparins.
Bianchini P; Liverani L; Spelta F; Mascellani G; Parma B
Semin Thromb Hemost; 2007 Jul; 33(5):496-502. PubMed ID: 17629846
[TBL] [Abstract][Full Text] [Related]
4. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
5. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue.
Fareed J; Haas S; Sasahar A
Semin Thromb Hemost; 1999; 25 Suppl 3():145-7. PubMed ID: 10549730
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy.
Guerrini M; Guglieri S; Naggi A; Sasisekharan R; Torri G
Semin Thromb Hemost; 2007 Jul; 33(5):478-87. PubMed ID: 17629844
[TBL] [Abstract][Full Text] [Related]
7. Quantitative PCR and disaccharide profiling to characterize the animal origin of low-molecular-weight heparins.
Houiste C; Auguste C; Macrez C; Dereux S; Derouet A; Anger P
Clin Appl Thromb Hemost; 2009 Feb; 15(1):50-8. PubMed ID: 18805847
[TBL] [Abstract][Full Text] [Related]
8. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
[TBL] [Abstract][Full Text] [Related]
10. Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine.
Dietrich CP; Shinjo SK; Moraes FA; Castro RA; Mendes A; Gouvea TC; Nader HB
Semin Thromb Hemost; 1999; 25 Suppl 3():43-50. PubMed ID: 10549715
[TBL] [Abstract][Full Text] [Related]
11. Are the available low-molecular-weight heparin preparations the same?
Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
[TBL] [Abstract][Full Text] [Related]
12. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
Jeske W; Fareed J
Semin Thromb Hemost; 1999; 25 Suppl 3():27-33. PubMed ID: 10549713
[TBL] [Abstract][Full Text] [Related]
13. Structural characterization of low molecular weight heparins.
Casu B; Torri G
Semin Thromb Hemost; 1999; 25 Suppl 3():17-25. PubMed ID: 10549712
[TBL] [Abstract][Full Text] [Related]
14. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis.
Davidson BL
Semin Thromb Hemost; 1999; 25 Suppl 3():107-12. PubMed ID: 10549725
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic profile of a low-molecular-weight heparin depolymerized by gamma-irradiation.
Jeske W; Iqbal O; Gonnela S; Boveri G; Torri G; De Ambrosi L; Fareed J
Semin Thromb Hemost; 1995; 21(2):201-11. PubMed ID: 7660143
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular weight molluscan glycosaminoglycan from bivalve Katelysia opima (Gmelin).
Vijayabaskar P; Balasubramanian T; Somasundaram ST
Methods Find Exp Clin Pharmacol; 2008 Apr; 30(3):175-80. PubMed ID: 18597000
[TBL] [Abstract][Full Text] [Related]
18. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
Nicolau JC; Cohen M; Montalescot G
J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
[TBL] [Abstract][Full Text] [Related]
19. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
[TBL] [Abstract][Full Text] [Related]
20. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
Harenberg J
Clin Appl Thromb Hemost; 2011; 17(6):E158-64. PubMed ID: 21406409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
